Improving Access to Acute Leukemia Clinical Trials for Diverse Patients
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
['FUNDING_CAREER'] · DANA-FARBER CANCER INST · NIH-11109703
This effort aims to help more Black and Hispanic adults with acute leukemia join clinical trials, ensuring everyone has a fair chance at new treatments.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11109703 on ClinicalTrials.gov |
What this research studies
We know that clinical trials for aggressive blood cancers like acute myeloid and lymphoblastic leukemia often don't include enough Black and Hispanic adults, which can limit who benefits from new therapies. This project looks at why these differences exist, including how trials are designed, how doctors talk about them, and patient concerns. We plan to create new ways to review trial plans, empower healthcare providers, and address patient hesitations to make sure more people can access these important treatment options.
Who could benefit from this research
Good fit: This work is relevant to adult patients, aged 21 and older, diagnosed with acute myeloid or lymphoblastic leukemia, particularly those from Black and Hispanic communities.
Not a fit: Patients who are not seeking participation in acute leukemia clinical trials or who do not face barriers to enrollment may not directly benefit from this specific intervention.
Why it matters
Potential benefit: If successful, this work could lead to more equitable access to advanced treatments and high-quality care for diverse patients with acute leukemia.
How similar studies have performed: While disparities in clinical trial enrollment are recognized, this project proposes a novel, multilevel intervention specifically tailored to the unique care patterns of acute leukemia.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HANTEL, ANDREW — DANA-FARBER CANCER INST
- Study coordinator: HANTEL, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.